S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
10 Ways Entrepreneurs Can Navigate a Down Economy
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
A Woman Co-founder's Guide to Empowering Women in the Workplace and Advocating for Gender Equality
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Open vs. Anonymous Employee Feedback — Which is Better?
PwC Australia sidelines 9 directors as leak of tax information investigated
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Drought-struck Barcelona quenches thirst with costly desalination
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
10 Ways Entrepreneurs Can Navigate a Down Economy
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
A Woman Co-founder's Guide to Empowering Women in the Workplace and Advocating for Gender Equality
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Open vs. Anonymous Employee Feedback — Which is Better?
PwC Australia sidelines 9 directors as leak of tax information investigated
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Drought-struck Barcelona quenches thirst with costly desalination
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
10 Ways Entrepreneurs Can Navigate a Down Economy
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
A Woman Co-founder's Guide to Empowering Women in the Workplace and Advocating for Gender Equality
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Open vs. Anonymous Employee Feedback — Which is Better?
PwC Australia sidelines 9 directors as leak of tax information investigated
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Drought-struck Barcelona quenches thirst with costly desalination
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
10 Ways Entrepreneurs Can Navigate a Down Economy
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
A Woman Co-founder's Guide to Empowering Women in the Workplace and Advocating for Gender Equality
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Open vs. Anonymous Employee Feedback — Which is Better?
PwC Australia sidelines 9 directors as leak of tax information investigated
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Drought-struck Barcelona quenches thirst with costly desalination
Positive News SentimentPositive News
NASDAQ:VIGL

Vigil Neuroscience (VIGL) Stock Forecast, Price & News

$9.36
+0.12 (+1.30%)
(As of 05/26/2023 04:00 PM ET)
Compare
Today's Range
$8.71
▼
$9.37
50-Day Range
$8.11
▼
$12.20
52-Week Range
$2.25
▼
$16.77
Volume
23,700 shs
Average Volume
22,552 shs
Market Capitalization
$334.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.80
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Vigil Neuroscience MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
100.9% Upside
$18.80 Price Target
Short Interest
Bearish
3.87% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.22) to ($2.56) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.92 out of 5 stars

Medical Sector

717th out of 1,010 stocks

Biological Products, Except Diagnostic Industry

112th out of 169 stocks

See Top Rated MarketRank™ Stocks Here

VIGL stock logo

About Vigil Neuroscience (NASDAQ:VIGL) Stock

Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease. The company also develops a small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Cambridge, Massachusetts. Vigil Neuroscience, Inc. operates as a subsidiary of Amgen Inc.

Receive VIGL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vigil Neuroscience and its competitors with MarketBeat's FREE daily newsletter.

VIGL Stock News Headlines

May 17, 2023 | americanbankingnews.com
Vigil Neuroscience, Inc. (NASDAQ:VIGL) Expected to Earn FY2023 Earnings of ($2.14) Per Share
May 16, 2023 | americanbankingnews.com
Vigil Neuroscience, Inc. Forecasted to Earn FY2023 Earnings of ($1.85) Per Share (NASDAQ:VIGL)
May 29, 2023 | Behind the Markets (Ad)
"Unknown laser company making HUGE profit from Russia-Ukraine War"
On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>
May 13, 2023 | americanbankingnews.com
Vigil Neuroscience, Inc. Expected to Post Q1 2024 Earnings of ($0.51) Per Share (NASDAQ:VIGL)
May 12, 2023 | msn.com
Vigil Neuroscience: Q1 Earnings Insights
May 11, 2023 | markets.businessinsider.com
H.C. Wainwright Keeps Their Buy Rating on Vigil Neuroscience Inc (VIGL)
May 10, 2023 | finanznachrichten.de
Vigil Neuroscience, Inc.: Vigil Neuroscience Reports First Quarter 2023 Financial Results and Provides Business Update
May 10, 2023 | finance.yahoo.com
Vigil Neuroscience Reports First Quarter 2023 Financial Results and Provides Business Update
May 29, 2023 | Behind the Markets (Ad)
"Unknown laser company making HUGE profit from Russia-Ukraine War"
On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>
May 9, 2023 | finance.yahoo.com
Vigil Neuroscience Appoints Samantha Budd Haeberlein, Ph.D. to Board of Directors
May 8, 2023 | finance.yahoo.com
Vigil Neuroscience Launches ALSPAware to Provide Access to No-cost Genetic Testing and Counseling for Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP)
May 8, 2023 | finance.yahoo.com
Vigil Neuroscience (NASDAQ:VIGL) Is In A Good Position To Deliver On Growth Plans
April 15, 2023 | americanbankingnews.com
Comparing Revolution Medicines (NASDAQ:RVMD) & Vigil Neuroscience (NASDAQ:VIGL)
April 6, 2023 | americanbankingnews.com
ERYTECH Pharma (NASDAQ:ERYP) vs. Vigil Neuroscience (NASDAQ:VIGL) Financial Review
April 5, 2023 | americanbankingnews.com
Vigil Neuroscience (NASDAQ:VIGL) Stock Rating Reaffirmed by Wedbush
April 3, 2023 | benzinga.com
What 4 Analyst Ratings Have To Say About Vigil Neuroscience
March 31, 2023 | msn.com
Mizuho Initiates Coverage of Vigil Neuroscience (VIGL) with Buy Recommendation
March 31, 2023 | markets.businessinsider.com
Analysts Conflicted on These Healthcare Names: Cardinal Health (CAH), Alcon (ALC) and Vigil Neuroscience Inc (VIGL)
March 31, 2023 | americanbankingnews.com
Vigil Neuroscience (NASDAQ:VIGL) Coverage Initiated by Analysts at Mizuho
March 30, 2023 | markets.businessinsider.com
Vigil Neuroscience Inc (VIGL) Receives a New Rating from Mizuho Securities
March 30, 2023 | seekingalpha.com
Vigil surges after FDA lifts partial hold on neurological disorder drug VGL101
March 30, 2023 | finance.yahoo.com
Vigil Neuroscience Announces FDA Has Lifted the Partial Clinical Hold on VGL101
March 29, 2023 | americanbankingnews.com
Vigil Neuroscience (NASDAQ:VIGL) PT Raised to $13.00 at Morgan Stanley
March 28, 2023 | americanbankingnews.com
Comparing Vaxart (NASDAQ:VXRT) and Vigil Neuroscience (NASDAQ:VIGL)
March 26, 2023 | americanbankingnews.com
Vigil Neuroscience, Inc. to Post Q1 2023 Earnings of ($0.45) Per Share, HC Wainwright Forecasts (NASDAQ:VIGL)
March 23, 2023 | benzinga.com
Vigil Neuroscience Stock (NASDAQ:VIGL), Dividends
March 23, 2023 | americanbankingnews.com
Vigil Neuroscience, Inc. Expected to Earn Q1 2023 Earnings of ($0.49) Per Share (NASDAQ:VIGL)
See More Headlines
Receive VIGL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vigil Neuroscience and its competitors with MarketBeat's FREE daily newsletter.

VIGL Company Calendar

Last Earnings
3/21/2023
Today
5/29/2023
Next Earnings (Estimated)
8/14/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VIGL
CUSIP
N/A
CIK
1827087
Web
vigilneuro.com
Phone
857-254-4445
Fax
N/A
Employees
2,021
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$18.80
High Stock Price Forecast
$24.00
Low Stock Price Forecast
$13.00
Forecasted Upside/Downside
+100.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($2.12)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-68,310,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-40.60%
Return on Assets
-37.99%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
23.30
Quick Ratio
23.30

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$5.31 per share
Price / Book
1.76

Miscellaneous

Outstanding Shares
35,690,000
Free Float
19,045,000
Market Cap
$334.06 million
Optionable
Not Optionable
Beta
3.34

Key Executives

  • Dr. Ivana Magovcevic-Liebisch J.D. (Age 56)
    Ph.D., Pres, CEO & Director
    Comp: $713.25k
  • Ms. Jennifer Ziolkowski CPA (Age 49)
    CPA, Chief Financial Officer
    Comp: $518.04k
  • Dr. Spyridon Papapetropoulos M.D. (Age 50)
    Ph.D., Chief Medical Officer
    Comp: $601.74k
  • Park Guo CPA
    Accounting Mang.
  • Kelly Neelon Ph.D.
    VP of CMC & Technical Operations
  • Ms. Sarah Carmody
    VP of Investor Relations & Corp. Communications
  • Mr. Christopher Verni J.D. (Age 48)
    Gen. Counsel
  • April Effort M.B.A.
    M.S., Head of Corp. Devel.
  • Mr. Evan A. Thackaberry DABT (Age 50)
    Ph.D., Sr. VP & Head of Early Devel.
  • Mr. Charles Maggs
    Head of FP&A

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













VIGL Stock - Frequently Asked Questions

Should I buy or sell Vigil Neuroscience stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vigil Neuroscience in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VIGL shares.
View VIGL analyst ratings or view top-rated stocks.

What is Vigil Neuroscience's stock price forecast for 2023?

5 Wall Street research analysts have issued 1 year price objectives for Vigil Neuroscience's stock. Their VIGL share price forecasts range from $13.00 to $24.00. On average, they expect the company's stock price to reach $18.80 in the next twelve months. This suggests a possible upside of 100.9% from the stock's current price.
View analysts price targets for VIGL or view top-rated stocks among Wall Street analysts.

How have VIGL shares performed in 2023?

Vigil Neuroscience's stock was trading at $12.50 on January 1st, 2023. Since then, VIGL stock has decreased by 25.1% and is now trading at $9.36.
View the best growth stocks for 2023 here.

When is Vigil Neuroscience's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our VIGL earnings forecast.

How were Vigil Neuroscience's earnings last quarter?

Vigil Neuroscience, Inc. (NASDAQ:VIGL) released its quarterly earnings results on Tuesday, March, 21st. The company reported ($0.48) earnings per share for the quarter, topping the consensus estimate of ($0.62) by $0.14.

When did Vigil Neuroscience IPO?

(VIGL) raised $112 million in an initial public offering (IPO) on Friday, January 7th 2022. The company issued 7,000,000 shares at $15.00-$17.00 per share.

What is Vigil Neuroscience's stock symbol?

Vigil Neuroscience trades on the NASDAQ under the ticker symbol "VIGL."

Who are Vigil Neuroscience's major shareholders?

Vigil Neuroscience's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Geode Capital Management LLC (0.32%), Barclays PLC (0.29%), Citigroup Inc. (0.26%), Susquehanna International Group LLP (0.16%), Jane Street Group LLC (0.08%) and Bank of America Corp DE (0.05%). Insiders that own company stock include Christopher Verni, Clay Thorp, Evan Thackaberry, Ivana Magovcevic-Liebisch and Spyros Papapetropoulos.
View institutional ownership trends.

How do I buy shares of Vigil Neuroscience?

Shares of VIGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vigil Neuroscience's stock price today?

One share of VIGL stock can currently be purchased for approximately $9.36.

How much money does Vigil Neuroscience make?

Vigil Neuroscience (NASDAQ:VIGL) has a market capitalization of $334.06 million. The company earns $-68,310,000.00 in net income (profit) each year or ($2.12) on an earnings per share basis.

How many employees does Vigil Neuroscience have?

The company employs 2,021 workers across the globe.

How can I contact Vigil Neuroscience?

The official website for the company is vigilneuro.com. The company can be reached via phone at 857-254-4445 or via email at scarmody@vigilneuro.com.

This page (NASDAQ:VIGL) was last updated on 5/29/2023 by MarketBeat.com Staff

My Account -